Lemaire S, Livett B, Tseng R, Mercier P, Lemaire I
J Neurochem. 1981 Mar;36(3):886-92. doi: 10.1111/j.1471-4159.1981.tb01677.x.
In isolated bovine adrenal chromaffin cells, beta-endorphin, dynorphin, and levorphanol caused a dose-dependent inhibition of catecholamine (CA) secretion elicited by acetylcholine (ACh), with an ID50 of 50, 1.3, and 4.3 microM, respectively. The inhibition by the opiate compounds was specific for the release evoked by ACh and nicotinic drugs and was noncompetitive with ACh. Stereospecific binding sites for the opiate agonist [3H]etorphine were found in homogenates of bovine adrenal medulla (KD = 0.59 nM). beta-Endorphin, dynorphin, levorphanol, and naloxone were potent inhibitors of the binding of [3H]etorphine with an ID50 of 12, 0.4, 5.2, and 6.2 nM, respectively. However, [3,5-I2Tyr1]-beta-endorphin, [3,5-I2Tyr1]-dynorphin, and dextrorphan, three opiate compounds with no or little activity in the guinea pig ileum assay, were relatively ineffective in inhibiting the binding of [3H]etorphine (ID50 700, 600, and 10,000 nM, respectively). On the other hand, these three compounds were equipotent with beta-endorphin, dynorphin, and levorphanol, respectively, in inhibiting the ACh-evoked release of CA from the adrenal chromaffin cells (ID50 of 10, 1.5, and 6 microM, respectively). Inhibition of CA release was also obtained with naloxone (ID50 = 14) microM) and naltrexone (ID50 greater than 10(-4) M), two classical antagonists of opiate receptors, and this effect was additive to that of beta-endorphin. These data indicate that the opiate modulation of CA release from adrenal chromaffin cells is not related to the stimulation of the high affinity stereospecific opiate binding sites of the adrenal medulla. The physiological function of these sites remains to be determined.
在分离的牛肾上腺嗜铬细胞中,β-内啡肽、强啡肽和左啡诺对乙酰胆碱(ACh)引发的儿茶酚胺(CA)分泌产生剂量依赖性抑制,其半数抑制浓度(ID50)分别为50、1.3和4.3微摩尔。阿片类化合物的抑制作用对ACh和烟碱类药物引发的释放具有特异性,且与ACh无竞争性。在牛肾上腺髓质匀浆中发现了阿片激动剂[3H]埃托啡的立体特异性结合位点(解离常数KD = 0.59纳摩尔)。β-内啡肽、强啡肽、左啡诺和纳洛酮是[3H]埃托啡结合的有效抑制剂,其ID50分别为12、0.4、5.2和6.2纳摩尔。然而,[3,5-碘代酪氨酸1]-β-内啡肽、[3,5-碘代酪氨酸1]-强啡肽和右啡烷这三种在豚鼠回肠试验中无活性或活性很小的阿片类化合物,在抑制[3H]埃托啡结合方面相对无效(ID50分别为700、600和10000纳摩尔)。另一方面,这三种化合物在抑制肾上腺嗜铬细胞中ACh引发的CA释放方面,分别与β-内啡肽、强啡肽和左啡诺等效(ID50分别为10、1.5和6微摩尔)。纳洛酮(ID50 = 14微摩尔)和纳曲酮(ID50大于10^-4摩尔)这两种经典的阿片受体拮抗剂也能抑制CA释放,且这种作用与β-内啡肽的作用具有相加性。这些数据表明,阿片类物质对肾上腺嗜铬细胞CA释放的调节与肾上腺髓质高亲和力立体特异性阿片结合位点的刺激无关。这些位点的生理功能尚待确定。